Decentralized Trial Economics
When DCT works — and when it doesn’t.
A defensible view of decentralized clinical trial economics — when DCT actually accelerates timelines and when it adds operational cost without speed.
"Should this trial run decentralized, hybrid or site-only?"
DCT helps retention more than recruitment. Hybrid often beats fully decentralized. Match modality to indication carefully.
Decentralized trials are now mainstream. Most teams find hybrid DCT delivers the retention and patient-experience gains without the operational complexity of fully-decentralized.
What we’re seeing in the data.
Retention beats recruitment lift
DCT primarily helps keep enrolled patients.
Hybrid is the practical winner
Pure DCT works only for narrow trial types.
Tech-stack overhead is real
Wearable + telemedicine + drug-shipment integration.
How to think about it.
-
01
Score indication fit
Visit burden, monitoring complexity.
-
02
Choose modality
Site-only / hybrid / fully decentralized.
-
03
Plan tech stack
eConsent, wearables, telemedicine.
-
04
Model economics
Per-patient cost vs timeline.
What separates a good answer from a defensible one.
Improving but variable.
Older patients may struggle.
Remote endpoints variance.
Where the signal comes from.
Common questions.
Is fully-DCT a real option?
For specific trial types yes; mostly hybrid is what scales.
Does DCT cost less?
Often per-site less; per-patient sometimes more.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist